Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 11, 2014, Pages 1240-1246

  Löwenberg, Mark ^a   Duijvis, Nicolette W ^a   Ponsioen, Cyriel ^a   Van Den Brink, Gijs R ^a   Fockens, Paul ^a   D'Haens, Geert R A M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Costs; Cyclosporine; Infliximab; Length of hospital stay; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; TACROLIMUS; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COLON RESECTION; DRUG COST; FEMALE; GASTROENTEROLOGY; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PANCOLITIS; PATIENT SELECTION; PRIORITY JOURNAL; TERTIARY CARE CENTER; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; ECONOMICS; HEALTH SERVICES RESEARCH; KAPLAN MEIER METHOD; LENGTH OF STAY; NETHERLANDS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; CYCLOSPORINE; DRUG COSTS; FEMALE; GASTROINTESTINAL AGENTS; HEALTH SERVICES RESEARCH; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LENGTH OF STAY; MALE; NETHERLANDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84927591022     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000187     Document Type: Article

References (18)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4:299-315.
2. Dinesen LC, Walsh AJ, Protic M.N., Heap G., Cummings F, Warren BF, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010; 4:431-437.
3. Truelove CS, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1:1067-1070.
4. Järnerot G, Rolny P, Sandberg-Gertzén H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89:1005-1013.
5. Bernal I, Mañosa M, Domènech E, Garcia-Planella E, Navarro M, Lorenzo-Zúñiga V, et al. Predictors of clinical response to systemic steroids in active ulcerative colitis. Dig Dis Sci 2006; 51:1434-1438.
6. Lichtiger S, Present DH, Kornbluth A, Gelernt I., Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
7. Van Assche G, D'Haens G, Noman M, Vermeire S., Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125:1025-1031.
8. Moskovitz DN, Van Assche G, Maenhout B, Arts J., Ferrante M, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:760-765.
9. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10:73-78.
10. Rutgeerts P, Sandborn WJ, Feagan B.G., Reinisch W., Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
11. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L., Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-1811.
12. Kohn A, Daperno M, Armuzzi A., Cappello M, Biancone L, Orlando A., et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007; 26:747-756.
13. Laharie D, Bourreille A, Branche J., Allez M, Bouhnik Y, Filippi J., et al. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380:1909-1915.
14. Dignass A, Lindsay JO, Sturm A, Windsor A., Colombel JF, Allez M, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6:991-1030.
15. Travis SP, Farrant JM, Ricketts C, Nolan D.J., Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-910.
16. Lichtenstein GR, Feagan BG, Cohen R.D., Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT" registry. Am J Gastroenterol 2012; 107:1409-1422.
17. Appau KA, Fazio VW, Shen B, Church J.M., Lashner B., Remzi F, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12:1738-1744.
18. Chaudhary MA, Fan T. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis in the Netherlands. Biol Ther 2013; 3:45-60.